<DOC>
	<DOCNO>NCT01398267</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , parallel-group study evaluate effect aleglitazar renal function , renin-angiotensin system pharmacokinetics lisinopril patient type 2 diabetes mellitus treat lisinopril . Patients stable dose lisinopril ( 20 mg daily orally ) 2 week randomize receive either aleglitazar ( 150 mcg orally daily ) placebo addition lisinopril 4 week .</brief_summary>
	<brief_title>A Pharmacodynamic/Pharmacokinetic Study Aleglitazar Patients With Type 2 Diabetes Mellitus Treatment With Lisinopril</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Lisinopril</mesh_term>
	<criteria>Adult male female patient , 18 65 year age , inclusive Diabetes mellitus Type 2 , diagnose least 3 month screen Treated stable dose metformin least 4 week prior screen Treated stable dose Angiotensinconverting enzyme inhibitor ( ACEI ) least 4 week prior screen Body mass index ( BMI ) 18 38 kg/m2 , inclusive Positive HIV1 , HIV2 , hepatitis B hepatitis C infection Pregnant lactating female Type 1 diabetes secondary diabetes History evidence proliferative diabetic retinopathy clinically significant neuropathy Clinically significant hepatic disease Clinically significant renal impairment History evidence clinically significant cardiovascular disease disorder Acute infection current malignancy require treatment except excise basal cell carcinoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>